GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » COGS-to-Revenue

CARISMA Therapeutics (CARISMA Therapeutics) COGS-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics COGS-to-Revenue?

CARISMA Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $3.40 Mil.

CARISMA Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. CARISMA Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

CARISMA Therapeutics COGS-to-Revenue Historical Data

The historical data trend for CARISMA Therapeutics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics COGS-to-Revenue Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- - - -

CARISMA Therapeutics Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CARISMA Therapeutics COGS-to-Revenue Calculation

CARISMA Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 14.919
=0.00

CARISMA Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 3.397
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics  (NAS:CARM) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

CARISMA Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 3.397
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

CARISMA Therapeutics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (CARISMA Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (NAS:CARM) » Definitions » COGS-to-Revenue
Comparable Companies
TSVT PLX CDXS TALS ABSI DSGN PEPG TRVI ADAP CTXR OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
W2J:Germany
Address
245 First Street, Suite 1800, Cambridge, MA, USA, 02142
Website
https://www.carismatx.com
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Executives
Modernatx, Inc. 10 percent owner 200 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Sanford S Zweifach director 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021
Steven Kelly director, officer: President and CEO C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341
Chidozie Ugwumba director 158 FILMORE STREET, DENVER CO 80206
Michael Klichinsky officer: Chief Scientific Officer C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Michael Torok director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Regina Hodits director C/O CARISMA THERAPEUTICS INC., 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bjorn Odlander director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Minori Rosales officer: Chief Development Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Jewett Michael A. S. director C/O SESEN BIO, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Peter Honig director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Patricia M. Drake officer: Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Elly Ryu officer: Principal Accounting Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142